{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:01:06Z","timestamp":1776394866391,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Health Commission of Jiangxi Province of China","award":["20203335"],"award-info":[{"award-number":["20203335"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060574"],"award-info":[{"award-number":["82060574"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04911-4","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:14:59Z","timestamp":1767424499000},"page":"8503-8515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial"],"prefix":"10.1007","volume":"399","author":[{"given":"Ougen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caixia","family":"Kou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huizhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"12","key":"4911_CR1","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/1346-8138.17009","volume":"50","author":"A Alegre-Bailo","year":"2023","unstructured":"Alegre-Bailo A, S\u00e1nchez-Gilo A, Rom\u00e1n Mendoza NM, Mateos-Rico JJ, Vicente-Mart\u00edn FJ (2023) Tralokinumab treatment in atopic dermatitis: depicting super-responders. J Dermatol 50(12):1650\u20131652","journal-title":"J Dermatol"},{"issue":"19","key":"4911_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323(19):1945\u20131960","journal-title":"JAMA"},{"issue":"10","key":"4911_CR3","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1159\/000525723","volume":"183","author":"B Arslan","year":"2022","unstructured":"Arslan B, Pa\u00e7ac\u0131 \u00c7etin G, T\u00fcrk M, G\u00fclmez \u0130, Y\u0131lmaz \u0130 (2022) Discontinuing omalizumab treatment in super-responder patients with allergic severe asthma: can the baseline total IgE level be used as a biological marker to decide discontinuing omalizumab treatment? Int Arch Allergy Immunol 183(10):1071\u20131077","journal-title":"Int Arch Allergy Immunol"},{"issue":"10","key":"4911_CR4","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1080\/02770903.2023.2196562","volume":"60","author":"ME Cakmak","year":"2023","unstructured":"Cakmak ME, \u00d6ztop N, Ye\u011fit OO, \u00d6zdedeo\u011flu \u00d6 (2023) Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study. J Asthma 60(10):1862\u20131868","journal-title":"J Asthma"},{"issue":"9","key":"4911_CR5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","volume":"160","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, Sabat R, Wolk K, Eyerich S, Lauffer F, Angsana J, Taut FJH, Kohler K, Chen Y, Sendecki J, Leung MWL, Wegner S, Personke Y, Gomez M, Kr\u00fcger N, Tabori S, Sch\u00e4kel K (2024) Noninferiority of 16-week vs 8-week Guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial. JAMA Dermatol 160(9):953\u2013963","journal-title":"JAMA Dermatol"},{"issue":"3","key":"4911_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK (1994) Dermatology life quality index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210\u2013216","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"4911_CR7","first-page":"562","volume":"108","author":"KK Garner","year":"2023","unstructured":"Garner KK, Hoy KDS, Carpenter AM (2023) Psoriasis: recognition and management strategies. Am Fam Physician 108(6):562\u2013573","journal-title":"Am Fam Physician"},{"issue":"10281","key":"4911_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J (2021) Psoriasis. Lancet (London, England) 397(10281):1301\u20131315","journal-title":"Lancet (London, England)"},{"issue":"2","key":"4911_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5414\/CP204495","volume":"62","author":"S Hamada","year":"2024","unstructured":"Hamada S, Ogino E, Yasuba H (2024) Super-responder and clinical remission in patients with asthma on treatment with single biologic therapy or cycling therapy using dupilumab in a real-world setting. Int J Clin Pharmacol Ther 62(2):61\u201368","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4911_CR10","doi-asserted-by":"publisher","first-page":"711060","DOI":"10.3389\/fimmu.2021.711060","volume":"12","author":"Y Hao","year":"2021","unstructured":"Hao Y, Zhu YJ, Zou S, Zhou P, Hu YW, Zhao QX, Gu LN, Zhang HZ, Wang Z, Li J (2021) Metabolic syndrome and psoriasis: mechanisms and future directions. Front Immunol 12:711060","journal-title":"Front Immunol"},{"issue":"7","key":"4911_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40261-023-01280-9","volume":"43","author":"P Herranz-Pinto","year":"2023","unstructured":"Herranz-Pinto P, Alonso-Pacheco ML, Feltes-Ochoa R, Mayor-Ibarguren A, Servera-Negre G, Busto-Leis JM, Gonzalez-Fern\u00e1ndez MA, Herrero-Ambrosio A (2023) Real-world performance of a new strategy for off-label use of Guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and optimisation. Clin Drug Investig 43(7):517\u2013527","journal-title":"Clin Drug Investig"},{"issue":"3","key":"4911_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/1346-8138.14096","volume":"45","author":"M Kamata","year":"2018","unstructured":"Kamata M, Tada Y (2018) Safety of biologics in psoriasis. J Dermatol 45(3):279\u2013286","journal-title":"J Dermatol"},{"key":"4911_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051690","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y (2020) Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21051690","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4911_CR14","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s40265-024-02110-8","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ (2024) Vunakizumab: first approval. Drugs 84(11):1481\u20131485","journal-title":"Drugs"},{"issue":"5","key":"4911_CR15","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/bjd.13691","volume":"172","author":"H Kitchen","year":"2015","unstructured":"Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C (2015) Patient-reported outcome measures in psoriasis: the good, the bad and the missing! Br J Dermatol 172(5):1210\u20131221","journal-title":"Br J Dermatol"},{"issue":"10","key":"4911_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16(10):626\u2013638","journal-title":"Nat Rev Immunol"},{"issue":"19","key":"4911_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2106\/JBJS.O.00030","volume":"97","author":"NC Laucis","year":"2015","unstructured":"Laucis NC, Hays RD, Bhattacharyya T (2015) Scoring the SF-36 in orthopaedics: a brief guide. J Bone Joint Surg Am 97(19):1628\u20131634","journal-title":"J Bone Joint Surg Am"},{"key":"4911_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713313","author":"HJ Lee","year":"2023","unstructured":"Lee HJ, Kim M (2023) Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241713313","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4911_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2331782","volume":"35","author":"Y Liu","year":"2024","unstructured":"Liu Y, Hu K, Jian L, Duan Y, Zhang M, Kuang Y (2024) Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year. J Dermatolog Treat 35(1):2331782","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"4911_CR20","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/jdv.18126","volume":"36","author":"N Loft","year":"2022","unstructured":"Loft N, Egeberg A, Rasmussen MK, Bryld LE, Nissen CV, Dam TN, Ajgeiy KK, Iversen L, Skov L (2022) Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study. J Eur Acad Dermatol Venereol: JEADV 36(8):1284\u20131291","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"issue":"3","key":"4911_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/bjd\/ljad446","volume":"190","author":"KJ Mason","year":"2024","unstructured":"Mason KJ, Alabas OA, Dand N, Warren RB, Reynolds NJ, Barker J, Yiu ZZN, Smith CH, Griffiths CEM (2024) Characteristics of \u201csuper responders\u201d and \u201csuper nonresponders\u201d to first biologic monotherapy for psoriasis: a nested case-control study. Br J Dermatol 190(3):441\u2013444","journal-title":"Br J Dermatol"},{"issue":"4","key":"4911_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 80(4):1029\u20131072","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"4911_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.36849\/JDD.6443","volume":"21","author":"H Naidu","year":"2022","unstructured":"Naidu H, Karagaiah P, Patil A, Yamauchi P, Kircik L, Grabbe S, Goldust M (2022) New biologics and oral drugs in treatment of moderate to severe psoriasis. J Drugs Dermatol 21(8):826\u2013831","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"4911_CR24","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1365-2133.2011.10469.x","volume":"165","author":"MF Otuki","year":"2011","unstructured":"Otuki MF, Reis RC, Cabrini D, Prudente AS, Horinouchi CD, Correr CJ (2011) Patient-reported outcomes in psoriasis research and practice. Br J Dermatol 165(6):1361\u20131362","journal-title":"Br J Dermatol"},{"issue":"12","key":"4911_CR25","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.mayocp.2015.08.017","volume":"90","author":"V Prasad","year":"2015","unstructured":"Prasad V, Vandross A (2015) Characteristics of exceptional or super responders to cancer drugs. Mayo Clin Proc 90(12):1639\u20131649","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"4911_CR26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/ijd.15784","volume":"61","author":"R Ruiz-Villaverde","year":"2022","unstructured":"Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M (2022) Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series. Int J Dermatol 61(8):1029\u20131033","journal-title":"Int J Dermatol"},{"issue":"10","key":"4911_CR27","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","volume":"37","author":"K Sch\u00e4kel","year":"2023","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, Paul C, Gomez M, Wegner S, Personke Y, Kreimendahl F, Chen Y, Angsana J, Leung MWL, Eyerich K (2023) Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol 37(10):2016\u20132027","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"4911_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jdv.17870","volume":"36","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, Williams N, Sciascia T, Augustin M (2022) Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol: JEADV 36(4):573\u2013581","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"issue":"5","key":"4911_CR29","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/bjd\/ljad280","volume":"189","author":"SE Thomas","year":"2023","unstructured":"Thomas SE, van den Reek J, Seyger MMB, de Jong E (2023) How to define a \u201csuper-responder\u201d to biologics in psoriasis studies. Br J Dermatol 189(5):621\u2013622","journal-title":"Br J Dermatol"},{"issue":"3","key":"4911_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","volume":"42","author":"AM Wride","year":"2024","unstructured":"Wride AM, Chen GF, Spaulding SL, Tkachenko E, Cohen JM (2024) Biologics for psoriasis. Dermatol Clin 42(3):339\u2013355","journal-title":"Dermatol Clin"},{"issue":"6","key":"4911_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","volume":"36","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF (2022) Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol: JEADV 36(6):797\u2013806","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"issue":"1","key":"4911_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2024.09.031","volume":"92","author":"K Yan","year":"2025","unstructured":"Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, Li Y, Zhang L, Wang X, Li L, Lu J, Xu A, Yang S, Lu Y, Sun J, Li Z, Zhu X, Jiang M, Zhang S, Wang W, Li Y, Meng Z, Li H, Mou K, Han X, Li S, Chen A, Li X, Liu D, Zhang C, Ji C, Wang Y, Cheng H, Cui X, Yao X, Bai X, Dong G, Xu J (2025) Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol 92(1):92\u201399","journal-title":"J Am Acad Dermatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04911-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04911-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04911-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:38:50Z","timestamp":1776393530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04911-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4911"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04911-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a post-hoc exploratory analysis of a phase III trial, and the ethics approval number for the principal center (Huashan Hospital, Fudan University) was 20201231.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}